Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) EV-to-EBIT : 0.00 (As of May. 04, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cancer Prevention Pharmaceuticals's Enterprise Value is $0.00 Mil. Cancer Prevention Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 was $-3.98 Mil. Therefore, Cancer Prevention Pharmaceuticals's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

CPP's EV-to-EBIT is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 17.86
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cancer Prevention Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 was $0.00 Mil. Cancer Prevention Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 was $-3.98 Mil. Cancer Prevention Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2016 was %.

Cancer Prevention Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals EV-to-EBIT Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

EV-to-EBIT

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Cancer Prevention Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's EV-to-EBIT falls into.

Cancer Prevention Pharmaceuticals EV-to-EBIT Calculation

Cancer Prevention Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-3.976
	=	0.00

Cancer Prevention Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Cancer Prevention Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.98 Mil.

Cancer Prevention Pharmaceuticals (AMEX:CPP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cancer Prevention Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2016 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2016 )	=	EBIT	/	Enterprise Value (Q: Mar. 2016 )
	=	-3.976	/	0
	=	%

Cancer Prevention Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 was $0.00 Mil.
Cancer Prevention Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.98 Mil.

Cancer Prevention Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.